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EKSPRESI"INSULIN-LIKE GROWTH FACTORS" DAN RESEPTORNYA 
PADA PERINGKAT PRAIMPLANTASI DALAM TISU REPRODUKTIF 
MENCIT DIABETES 
ABSTRAK 
Kami menghipotesis bahawa embrio praimplantasi yang berkembang dalam 
persekitaran diabetes mengalami kekurangan faktor pertumbuhan tertentu. 
Tujuan utama kajian ini adalah untuk menentukan kesan diabetes ke atas 
perkembangan embrio praimplantasi mencit secara in vitro dan menganalisis 
ekspresi mRNA dan protein IGF-1, IGF-2, IGF-1 R dan IGF-2R dalam tisu 
fallopio dan uterus mencit kontrol dan diabetes. Mencit ICR betina yang matang 
secara seksual berusia 6 hingga 8 minggu dijadikan diabetes dengan suntikan 
streptozotosin (200 mg/kg, intra peritoneum). Embrio normal dalam peringkat 2-
sel diperolehi daripada mencit kontrol dan diabetes yang diseperovulasi pada 
48 jam pasca rawatan korionik gonadotropin manusia (hCG). Embrio dikultur 
secara berasingan dan diperiksa di bawah mikroskop songsang selama 3 hari 
berturut-turut. Tisu fallopio dan uterus diperolehi daripada mencit kontrol dan 
diabetes yang disuperovulasi pada 48, 72 dan 96 jam pasca rawatan hCG. 
Kuantifikasi ekspresi mRNA menggunakan tindak balas polimerase masa nyata 
menggunakan piawai internal homologus yang dibangunkan secara spesifik 
untuk setiap gen. Ekspresi protein menggunakan pewarnaan imunohistokimia 
dijalankan ke atas tisu dan skor semikuantitatif dibuat berdasarkan sistem 5-
skala piawai. Bilangan embrio 2-sel yang diperolehi daripada mencit diabetes 
xxiii 
adalah sangat berkurangan apabila dibanding dengan mencit kontrol. Walau 
bagaimanapun, tiada perbezaan yang signifikan dalam peratus perkembangan 
embrio 2-sel mencit kontrol dan diabetes. Ekspresi mRNA IGF-1 tisu fallopio 
dan uterus mencit diabetes rendah secara signifikan masing-masing pada 72 
dan 96 jam pasca rawatan hCG. Ekspresi mRNA IGF-1 R kekal tinggi dalam tisu 
fallopio tetapi rendah secara signifikan dalam tisu uterus mencit diabetes pada 
96 jam pasca rawatan hCG. Ekspresi mRNA IGF-2 tisu fallopio mencit diabetes 
tinggi secara signifikan pada 48 dan 96 jam pasca rawatan hCG tetapi rendah 
secara signifikan dalam tisu uterus mencit diabetes pada 96 jam pasca rawatan 
hCG. Ekspresi mRNA IGF-2R tisu fallopio dan uterus mencit diabetes tinggi 
secara signifikan masing-masing pada 48 dan 96 jam, dan 48 jam pasca 
rawatan hCG. Untuk ekspresi protein, skor imunohistokimia IGF-1 dan IGF-1 R 
berkurang secara signifikan dalam tisu fallopio pada 96 jam pasca rawatan 
hCG. Skor IGF-2 dan IGF-2R sebaliknya bertambah secara signifikan dalam 
tisu fallopio mencit diabetes masing-masing pada 48 dan 72 jam, dan pada 72 
jam pasca rawatan hCG. Walau bagaimanpun, tiada perbezaan skor yang 
signifikan bagi IGFs dan reseptornya dalam tisu uterus mencit kontrol dan 
diabetes. Sebagai kesimpulan, peratus perkembangan embrio 2-sel kepada 
blastosista adalah serupa di dalam mencit kontrol dan diabetes tetapi tidak. 
dapat disahkan sama ada kualiti embrio tersebut sama atau tidak. Ekspresi 
mRNA dan protein IGFs dan reseptor masing-masing mengalami perubahan 
yang signifikan akibat kesan diabetes ibu, mencadangkan wujudnya peranan 
mereka dalam patogenesis embriopati diabetes. 
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THE EXPRESSION OF INSULIN-LIKE GROWTH FACTORS AND THEIR 
RECEPTORS AT PRE IMPLANTATION STAGE IN REPRODUCTIVE 
TISSUES OF DIABETIC MOUSE 
ABSTRACT 
We hypothesized that the alteration in the expression of IGFs and their 
receptors may create an abnormal intrauterine environment thus affect embryos 
development. Therefore, the aims of the present study were to determine the 
effects of diabetes on in vitro development of mouse preimplantation embryos 
and to determine the mRNA and protein expression of IGF-1, IGF-2, IGF-1 R 
and IGF-2R in the fallopian tube and uterine tissue of control and diabetic mice. 
Sexually mature female ICR mice of 6-8 weeks old were made diabetic by 
streptozotocin (200 mg/kg, intraperitoneal). The normal two-cell embryos were 
obtained from superovulated control and diabetic mice at 48 post-hCG 
treatment. Embryos were separately cultured and examined under an inverted 
microscope for 3 consecutive days. Fallopian tubes and uterine tissues were 
obtained from the superovulated control and diabetic mice at 48, 72 and 96 
hours post-hCG treatment. The mRNA expression was measured using Real-
time PCR using specifically developed homologous internal standards for each 
gene. Protein expression was measured by immunohistochemical staining and 
a semiquantitative scoring was performed using a standardized 5-scale system. 
The number of normal two-cell embryos obtained from diabetic mice was much 
reduced when compared to control mice. However, there was no significant 
XXV 
difference in the percentage of two-eel! embryo development in control and 
diabetic mice. The mRNA expression of IGF-1 in the fallopian tube and uterus 
of diabetic mice was significantly low at 72 hours and 96 hours post-hCG 
treatment, respectively. The mRNA expression of IGF-1 R remained high in the 
fallopian tube but was significantly low in the uterus of diabetic mice at 96 hours 
post-hCG treatment. The mRNA expression IGF-2 in the fallopian tube was 
significantly high at 48 and 96 hours post-hCG treatment but was significantly 
low in the uterus of diabetic mice at 96 hours post-hCG treatment. The mRNA 
expression of IGF-2R in the fallopian tube and uterus of diabetic mice was 
significantly high at 48 and 96 hours, and at 48 hours post-hCG treatments, 
respectively. For protein expression, the immunohistochemical scoring for both 
IGF-1 and IGF-1 R was significantly decreased in the fallopian tube of diabetic 
mice at 96 hours post-hCG treatment. In contrast, the score for IGF-2 and IGF-
2R was significantly increased in the fallopian tube of diabetic mice at 48 and 72 
hours; and at 72 hours post-hCG treatment, respectively. However, there was 
no significant difference in the score of IGFs and their receptors in the uterus of 
control and diabetic mice. In conclusion, the percentage of the two-cell stage 
embryos which developed to blastocysts was similar in control and diabetic 
groups but whether the quality of these embryos were the same could not be 
confirmed. Both the mRNA and protein expression of IGFs and their receptors 
were significantly altered by maternal diabetes, which suggest their role in the 
pathogenesis of diabetic embryopathy. 
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CHAPTER ONE 
GENERAL INTRODUCTION 
1.1 PHYSIOLOGY OF PREIMPLANTATION EMBRYO DEVELOPMENT 
1.1.1 Proliferation and differentiation of preimplantation embryo 
Fertilization of the mouse ovum by sperm occurs in the ampullary region 
of the fallopian tube. Subsequent development occurs as the embryo moves 
down the fallopian tube and into the uterus over a period of about four days in 
mice, as compared to five and seven days in rats and humans, respect!vely 
(Figure 1.1 ). Approximately 24 hours after fertilization, the embryo undergoes 
relatively synchronous cell division resulting in the formation of two cells or 
blastomers. There are no junctions established between the individual cells, 
which are held together by ionic attractions on the opposing plasma membranes 
(Chavez, 1984). The cells are constrained within a physical shell, the zona 
pellucida, which is a matrix of four glycoproteins (Wassarman and Mortillo, 
1991 ). During this period, each blastomere is totipotent, retaining the capacity to 
form a complete fetus. Further mitotic divisions occur asynchronously at 
progressively shorter intervals so that from the eight-cell stage onwards, one 
cell cycle is approximately six hours. At the eight-cell stage, generation of two 
distinct lineages commences with the process of compaction when individual 
blastomers polarize, become epithelial-like and flatten on each other, 
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Figure 1.1 Development of the preimplantation embryo in mice from 
embryonic Day 1 through Day 4 
(Adapted from Hogan eta/., 1986) 
The fertilization takes place in the ampullary region of ·the fallopian tube and the 
developing embryo traverse down to the site of implantation in the uterine cavity. 
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maximising cell contact and forming tight and gap junctions (Ducibella et a!., 
1977; Magnuson and Epstein, 1981; Chavez, 1984; Fleming eta!., 1992). This 
compacted morula stage coincides with the arrival of the embryo at the utero-
tubal junction. In the compacted morula, fluid is transported across the newly 
formed epithelium to form a blastocoel and at this point the embryo is referred 
to as a blastocyst. At this stage, two distinct cell populations can be recognized 
(Johnson, 1981 ). The eccentrically placed inner cell mass (ICM) eventually 
forms the embryo proper and some extraembryonic tissues. The trophectoderm 
(TE}, which is a single epithelial layer of flattened cells surrounding the 
blastocoel and ICM, establishes the foci of adhesion with the uterine epithelium 
and gives rise to the fetal component of the placenta (Hogan eta!., 1986). 
1.1.2 Metabolic activity of preimplantation embryo 
Mouse oocyte and zygote have an absolute requirement for pyruvate 
(Biggers et a/., 1967); i.e. glucose cannot support early embryo development 
until the eight-cell stage (Biggers, 1971). From the two-cell to the blastocyst 
stage, the embryos experience an increase in the tricarboxylic acid (TCA) cycle 
metabolites and a dramatic increase in fructose 1, 6-biphosphate (FBP). The 
dramatic switch from a dependence on the TCA to a metabolism based on 
glycolysis occurs at the time of compaction. The only source of adenosine 
triphosphate (ATP) for the preimplantation embryo would be conversion of 
glucose to pyruvate and lactate via glycolysis. 
The blastocyst stage marks a new peak in cellular proliferation and 
growth. These changes create new biosynthetic demands on the embryos. 
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Maintenance of a high rate of glycolysis is important for providing a "dynamic 
buffer" of metabolic intermediates for the biosynthesis of macromolecules 
(Newsholme and Newsholme, 1989) and increasing amount of glucose are 
converted to lactate at this stage in humans and rodents (Leese and Barton, 
1984). lnterspecies variations in the rate of glycolysis have been reported, 
higher in human blastocysts (Leese et a!., 1993) and lower in mouse 
blastocysts (Leese, 1991) compared to rat embryos. 
Blastocysts are actively engaged in the uptake and metabolism of 
maternally derived nutrients such as glucose (Leese, 1991 ). The major site of 
uptake regulation is likely to be the system of facilitative glucose transporters 
(GLUT) situated at the basolateral surface of the TE in mouse blastocysts 
(Aghayan eta/., 1992). 
1.1.3 Influence of maternal factors on preimplantation embryo 
development 
Although the activation of the embryonic genome provides the conceptus 
with a number of vital developmental signals (Kidder, 1992; Schultz and 
Heyner, 1992), its progression through the preimplantation period is also 
influenced by maternal factors present in the oviductal and uterine environment. 
Biggers (1981) proposed a theoretical model summarizing the 
physiological processes that influence the microenvironment of the 
preimplantation embryo. The composition of the microenvironment is 
determined by several transport mechanisms: between the embryo and the 
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secretions in which it is bathed, between the fallopian tube and uterus and the 
bathing secretions and further mixing is produced as the secretions flow up and 
down the reproductive tract as shown in Figure 1.2. 
Maternally-derived nutrients/factors can either be transudates from the 
maternal circulation such as glucose (Leese et a/., 1979, Wales and 
Edirisinghe, 1989; Gonzalez eta/., 1994) and insulin (Heyner eta/., 1989; Smith 
et a/., 1 993), or secretions by various uterine cells into the lumen such as 
growth factors (Pollard, 1 990; Song et a/., 2000) and cytokines (Pampfer et a/., 
1991; Robertson eta/., 2001) during the preimplantation period. 
1.2 DIABETIC PREGNANCY 
The association between maternal diabetes and the increased risk of 
congenital malformations has a long histbry and was first reported by LeCorche 
(1885). It is generally accepted that congenital malformations are the leading 
cause of death in the offspring of diabetic women (Kitzmiller et a/., 1978). The 
incidence of congenital malformations is approximately 6 to 9% in diabetic 
pregnancies, which is three- to four-fold higher than in the general population, 
and accounts for 33 to 66% of perinatal deaths (Reece and Hobbins, 1 9.86). 
The congenital malformations most commonly associated with maternal 
diabetes are listed in Table 1.1 (Reece and Hobbins, 1 986). However, none of 
the reported congenital malformations is pathognomonic for the diagnosis of 
diabetic embryopathy. 
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influence the microenvironment of the preimplantation embryo 
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Table 1.1 Congenital malformations in infants of diabetic mothers 
(Adapted from Reece and Hobbins, 1986) 
Structure 
Skeletal and 
Central Nervous System 
Cardiac 
Renal Anomalies 
Gastrointestinal 
Others 
Anomaly 
Caudal regression syndrome 
Neural tube defects excluding anencephaly 
Anencephaly with or withou.t herniation of neural elements 
Microcephaly 
Transposition of the great vessels with or without ventricular septal defects 
Ventricular septal defects 
Coarctation of the aorta with or without ventricular septal defects or patent ductus arteriosus 
Atrial septal defects 
Cardiomegaly 
Hydronepherosis 
Renal agenesis 
.Ureteral duplication 
Duodenal atresia 
Anorectal atresia 
Small left colon syndrome 
Single umbilical artery 
,, 
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1.3 DEFINITION OF "DIABETIC EMBRYOPATHY" 
The term "embryopathia diabetica" was coined by Mayer (1952) and was 
later replaced by the term "diabetic embryopathy'' (Passarge and Lenz, 1966). 
The concept of diabetic embryopathy initially encompassed the long-recognized 
newborn features such as macrosomia and organomegaly but was later 
broadened to include congenital malformations (Mayer and Camara, 1964). 
Presently, the same concept was separated into two different entities, diabetic 
embryopathy and diabetic fetopathy. Diabetic embryopathy occurs during 
embryogenesis, mainly from the end of blastogenesis until the period of 
organogenesis (between the 3rd and ih week of gestation) and is associated 
with congenital malformations (Kousseff, 1999). In contrast, diabetic fetopathy 
occurs during fetal development, after the 1oth week of gestation, and is not 
associated with malformations (Kousseff, 1999). Occasionally, diabetic 
embryopathy is associated with diabetic fetopathy. However, these two entities, 
both induced by maternal diabetes mellitus, have different windows of 
vulnerability and perhaps, different pathogenesis. 
1.4 AETIOLOGICAL FACTORS ASSOCIATED WITH DIABETIC 
EMBRYOPATHY 
It has been suggested that the absence of a specific malformation 
pattern for diabetic embryopathy signals the presence of several aetiological 
factors and mechanisms in diabetic pregnancy (Khoury et a/., 1989). Likewise, 
the number of different teratogenic agents identified indicates that diabetic 
embryopathy is of complex aetiology (Sadler eta/., 1989; Zusman eta/., 1989; 
Buchanan eta/., 1994). 
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1.4.1 Maternal Hyperglycemia 
Hyperglycemia-induced teratogenic effects have been demonstrated in 
animal studies both in vivo and in vitro (Cockroft and Coppola, 1977; Baker et 
a/., 1981; Horton and Sadler, 1983; Kalter and Warkany, 1983a & 1983b; 
Freinkel eta/., 1986; Reece and Hobbins, 1986). The percentage of congenital 
malformations correlated with blood glucose levels (Reece et at., 1985) and 
glycosylated hemoglobin levels (Rose eta/., 1988). 
The period and time of exposure to hyperglycemia as well as the level of 
hyperglycemia are all important for dysmorphogenesis to occur. The critical 
period of exposure to hyperglycemia is during organogenesis, which is 
considered to be between days 9.5 to 11.5 in rats and 8.0 to 9.6 in mice 
(Freinkel, 1988), corresponding to the first 5 or 6 weeks of human pregnancy. A 
minimum exposure time of two or more hours is needed to induce these 
malformations. A -20% malformation rate was induced at glucose levels that 
were approximately two-fold above normal concentrations; an almost 50% 
malformation rate was seen at glucose levels three-fold above normal 
concentrations; and approximately 100% rate at six times above normal 
concentrations (Reece eta/., 1985). 
Maternal hyperglycemia adversely affects not only the postimplantation 
embryos but also preimplantation progression from one-cell to the blastocyst 
stage in a streptozotocin (STZ)-induced or a non-obese diabetic (NOD) mouse 
model (Diamond eta/., 1989; Moley eta/., 1991 & 1994). In the NOD model at 
96 hours after superovulation and mating, only 20% of the recovered embryos 
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reached blastocyst stage in the diabetic compared to 90% among the non-
diabetic. This developmental delay is reversible by treating the mothers with 
insulin before superovulation and mating and during the first 96 hours of 
gestation. This early preimplantation delay may be manifested later in gestation 
as fetal loss, early growth delay or congenital malformation. There is now 
convincing evidence that severe developmental anomalies leading to fetal 
resorption or malformation can occur as a consequence of subtle damage 
inflicted to the embryos before or at the time of implantation (Rutledge, 1997). 
The mechanism of hyperglycemia-induced congenital anomalies remains 
unclear. Hyperglycemia-induced reduction in GLUT has been proposed to be 
one of the possible mechanisms. A paradoxical reaction to hyperglycemia has 
been demonstrated in preimplantation embryos (Moley, 1999). In embryos of 
diabetic mice, a pronounced intracellular hypoglycemia was found despite 
maternal hyperglycemia (Moley et a/., 1998b). The decreased intracellular 
glucose concentration was associated with decreased GLUT namely, GLUT -1, 
GLUT-2 and GLUT-3 isoforms; both at the protein and mRNA levels (Moley et 
a/., 1998b). 
Reduced availability of glucose associated with decreased GLUT in 
diabetic embryos, results in significantly lower FBP and higher pyruvate, 
indicating decreased glycolysis and increased pyruvate uptake by the embryos, 
respectively. The glycolytic changes lead to dysfunction of the outer 
mitochondrial membrane and subsequently trigger the apoptotic cascade (Chi 
eta/., 2002). 
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The decrease in GLUT especially GLUT-1 and -3 isoforms also explains 
the elevated extracellular dehydroascorbate (DHA) and reduced intracellular 
ascorbic acid (Rumsey et a!., 1997) related to hyperglycemia as described 
previously (Ely, 1981 ). Ely (1981) proposed that reduced intracellular ascorbic 
acid resulted in decreased hexose monophosphate shunt activity (DeChatelet et 
a/., 1972), which might suppress deoxyribonucleic acid (DNA) synthesis as 
shown in Figure 1.3. Reduced DNA synthesis may slow cell division, leading to 
impaired cell proliferation or anomalies. It has also been suggested that 
elevated extracellular DHA may inhibit mitosis or cell proliferation (Edgar, 1970). 
This decrease in intracellular glucose concentration leads to a lower cell 
number in the ICM, either by increased apoptotic rate (Pampfer et a!., 1997b; 
Moley eta!., 1998a), or by diminished proliferation of these cells (Pampfer eta/., 
1990). Decrease in glucose transport and metabolism is not only related to 
progressive decrease in embryo viability but served as important regulatory 
points in the early apoptotic cascade (Johnson eta/., 1996; Li eta/., 1998; Shim 
et a!., 1998; Bialik et a/., 1999, Lin et a!., 2000). Maternal hyperglycemia, 
moreover, can cause direct disruption of the highly regulated gene program that 
controls the expression. pattern of crucial developmental determinants during 
early embryogenesis, including apoptosis (Phelan eta/., 1997; Cai eta/., 1998; 
Moley eta/., 1998a; Pampfer eta/., 2001 ). 
Three cell death paradigms that are linked to decreased GLUT include, 
(i) induction of ATP depletion and stimulation of the mitochondrial death 
cascade or (ii) induction of oxidative stress and triggering of Sax-associated 
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Figure 1.3 Mechanism of hyperglycemia-induced alterations in cell division and 
congenital anomalies 
(Adapted from Ely, 1981) 
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events including the c-Jun N-terminal kinase (JNK) and mitogen-activated 
protein kinase (MAPK) signalling pathways or (iii) regulation of expression of the 
gene encoding hypoxia-inducible factor 1 a. (HIF-1 a.) and the stabilization of p53 
by HIF-1 o: binding, leading to an increase in p53-associated apoptosis and, in 
turn, increased expression of Bax, and thus exaggerated apoptosis within 
blastocysts during glucose deprivation (Chi et a/., 2000; Moley and Mueckler, 
2000; Keim eta/., 2001 ). 
The outcome of apoptosis during preimplantation stage will depend on 
the percentage of cell death, if more than 60% of ICM undergo cell death, the 
pregnancy may result in fetal loss and resorption. However, the death of fewer 
cells (e.g. 40-45%) can result in either fetal resorption or malformation if this cell 
death involves key progenitor cells in development (Tam, 1988; Moley, 2001 ). 
Another possible mechanism of hyperglycemia-induced congenital 
anomalies that has been put forward is related to dysregulation in the uterine 
cytokine secretion (Pampfer, 2001). Diabetes-induced modifications in the 
oviductal and uterine concentrations of nutrients (such as increased glucose 
levels),. hormones (such as decreased insulin levels), growth factors, and 
cytokines (increased local synthesis of inhibitory factors or decreased local 
synthesis of stimulatory factors) are likely to elicit alterations in embryo 
development before implantation and organogenesis. 
Studies in STZ- and alloxan-treated diabetic mice exhibit an increased 
amount of tumour necrosis factor-a. (TNF-a.) messenger ribonucleic acid 
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(mRNA) and protein in the uterus and placenta of diabetic mice (Pampfer eta! .. 
1995; Flein eta/., 2001) as well as a marked reduction in pregnancy rate and a 
high incidence of litters with severely malformed fetuses (Torchinsky et a!., 
1997, Machado et a/., 2001 ). In addition, overexpression and excessive 
secretion of TNF-a by uterine cells in diabetic pregnancy may induce a 
decrease in cell number of the ICM as reported in an earlier study (Pampfer et 
a/., 1997b; Wuu eta!., 1999). 
TNF-a acts in a cell type- and stimulus-dependent manner, to generate 
apoptotic-signalling pathways (Baud and Karin, 2001; Gupta, 2001 ). The 
apoptotic action of TNF-a could occur mainly through its binding to the type 1 
receptor TN F-a, followed by the activation of caspase 8 (Siee eta/., 1999; Mohr 
eta/., 2002; Torchinsky eta/., 2003), which is considered to be among the main 
mediators o( apoptosis (Baud and Karin, 2001; Gupta, 2001 ). The apoptotic 
action of TN F-a could be mediated through interleukin-1 ~ (IL-1 ~) secreted by 
macrophages (Pampfer eta/., 1999) localized at the subepithelial region of the 
uterine stroma (Takacs eta/., 1988). 
The mechanism of hyperglycemia-induced IL-1 ~ secretion has been 
proposed to be via the formation and interaction of advanced glycation end 
products, AGE (VIassara et a/., 1988). Macrophages have a receptor that 
recognizes the AGE moiety and mediates the uptake and degradation of AGE 
proteins. This removal process is associated with the production and secretion 
of TN F-a and IL-1. The localized release and action of these cytokines may play 
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a role in the coordinated removal and replacement of senescent extracellular 
matrix (ECM) components in normal tissue homeostasis (VIassara eta/., 1988). 
1.4.2 Maternal Hyperketonemia 
The elevated glucagon-insulin ratio in diabetes mellitus enhances 
triglyceride hydrolysis by hormone-sensitive lipase and thereby increases 
plasma free fatty acid levels and also increases the uptake of these fatty acids 
by the liver. Acetyi-CoA carboxylase activity and malonyi-CoA concentrations 
are decreased in diabetes mellitus. Increased fatty acids and decreased 
malonyl-GoA result in increased 13-oxidation of fatty acids and the generation of 
acetyl-GoA. As a result, pyruvate carboxylase for gluconeogenesis is stimulated 
and ketone bodies production is increased. The ketone bodies are potential 
teratogens as they freely cross the placenta (Herrera, 2002) and may serve as 
a fuel source to the fetus under conditions of maternal fasting (Ruwe et a/., 
1991 ). A high concentration of ketone bodies (13-hydroxybutyrate and 
acetoacetate) leads to a decreased production of purines and pyrimidines by 
fetal rat brain tissue (Shambaugh eta/., 1984). 
Frienkel and colleagues (Freinkel eta/., 1986; Freinkel, 1988) have also 
shown that 13-hydroxybutyrate induced malformations in cultured rat embryos in 
a dose-related fashion. Combination of minimally teratogenic amounts of both 
glucose and 13-hydroxybutyrate during culture of rat embryos resulted in 
significantly greater reductions of somite number, crown-rump length, and mean 
embryo protein content than by either of these metabolites alone (F reinkel et a/., 
1986). Clinical studies, however, showed inconclusive correlation between 
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maternal ketonuria and an increased risk of psychomotor impairment in children 
but not malformation rates (Rizzo eta/., 1991). 
1.4.3 Maternal Hypoglycemia 
The effect of hypoglycemia in the genesis of birth defects remains 
unclear. Discrepancies exist between human and animal data regarding the 
teratogenic effect of hypoglycemia. In animal models, Buchanan and colleagues 
(1986) demonstrated that mild hypoglycemia caused a significant reduction in 
somite number, protein and DNA content of the embryos, which are suggestive 
of growth retardation. In contrast to the animal models, there is little evidence in 
humans that hypoglycemia is teratogenic (Kitzmiller eta/., 1991). 
1.4.4 Free Oxygen Radicals 
Hyperglycemia-induced oxidative stress or generation of reactive oxygen 
species (ROS) by the embryos is implicated by indirect evidence, such as 
phospholipid peroxidation, reduction in the intracellular levels of antioxidant 
enzymes (superoxide dismutase (SOD), catalase and glutathione peroxidase) 
and depletion of antioxidant (glutathione) buffer capacity (Eriksson and Borg, 
1993; Cederberg eta/., 2000) .. 
Hyperglycemia impairs inositol uptake by the embryos (Weigensberg et 
a/., 1990). The immediate effect of lowered inositol concentration would be 
decreased levels of the phosphoinositides (phosphoinositides, PI; 
phosphatidylinositol phosphate, PIP; and phosphatidylinositol bisphosphate, 
PIP2) and their products in the embryonic tissue (Strieleman eta/., 1992). A lack 
16 
of PIP2 would subsequently yield less inositol triphosphate (IP3) and 
diacylglycerol, both of which are stimulators of protein ki~ase C (PKC) activity. 
A lowered PKC activity would then exert a number of effects, including lowered 
activity of cytosolic phospholipase A2 (sPLA2), the key enzyme in the 
metabolism of triglycerides and phospholipids. 
Two major pathways of phospholipid peroxidation have been suggested 
in embryos under hyperglycemic conditions. One of them involves arachidonic 
acid (AA), which is released from the membrane by cPLA2 and converted into 
prostaglandin E2 (PGE2) by cyclooxygenase-2 (COX-2). A decrease of cPLA2 
activity would subsequently diminish the availability of free AA, and thus 
diminish the production and metabolism of PGE2 during critical period in 
organogenesis (Goldman eta/., 1985). In another pathway, AA is converted into 
PGE2-Iike isoprostanes, such as 8-isb-PGF2 and 8-iso-PGF2a· These PGE-Iike 
isoprostanes have been shown to have damaging effects in animal models and 
embryos. Studies have suggested a relationship between deficiency of AA with 
hyperglycemia and embryopathy, and conversely, the protective effect of 
supplementation with AA and decrease incidence of diabetic embryopathy 
(Goldman eta/., 1985, Pinter eta/., 1988, Reece eta/., 1996). 
There is evidence that hyperglycemia can degrade antioxidant enzyme 
defenses i.e. lower glutathione reductase and SOD activity (Li et a/., 1999), 
thereby allowing ROS to damage other enzymes and also structural proteins. 
Moreover, both glucose and its glycation products will generate radicals if free 
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iron (or copper) is present. In addition, ketone bodies are also reported to be 
able to generate ROS via cytochrome P450 (Christopher et a/., 1 995). 
Hyperglycemia-induced increase in ROS either from increased of its 
production (Liu and Gutterman, 2002) or from diminished antioxidant defense 
capacity (Li eta/., 1999) in the tissue results in mitochondrial swelling (Yang et 
a/., 1995b), DNA mutations (Lee et a/., 1999) and apoptosis (Phelan et a/., 
1997). 
Chronic and excessive oxidative stress disturbs a variety of stress-
sensitive signalling pathways that are associated with apoptosis, including the 
MAPK signalling pathway (Torres and Forman, 2003; Kyosseva, 2004). It has 
been demonstrated that the activity of extracellular signal-related kinase (ERK) 
1 and ERK 2 were decreased and the activity of JNK 1 and JNK 2 were 
increased in oxidative stress. ERKs are involved in cell survival, whereas JNKs 
play a role in promoting apoptosis through regulation of transcription factors 
(Lin, 2003; Wada and Penninger, 2004). Similarly, maternal diabetes impairs 
ERK and activates JNK signalling pathways, resulting in excessive apoptosis 
and embryon.ic malformations (Reece eta/., 2006) as illustrated in Figure 1.4. 
1.4.5 Genetic Susceptibility 
Women with similar metabolic control have different outcomes with 
regard to fetal malformations, suggesting the existence of genetic differences 
among women with diabetes. A genetic predisposition towards an increased 
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rate of embryonic dysmorphogenesis (Eriksson, 1988) may result from a 
diminished capacity to scavenge endogenously formed ROS. This is a capacity 
that can vary between strains (Salganik eta!., 1994; Hagay et a/., 1995) and 
tentatively, among pregnant diabetic women and their offsprings. 
One study reported that the frequency of congenital malformations in the 
offspring of STZ-induced diabetic rats differed among Sprague-Dawley 
substrains (Eriksson eta/., 1986) despite similar levels of carbohydrate and lipid 
metabolism. In the rat model, diabetic teratogenesis in the susceptible mothers 
appears to be potentiated in the presence of genetically predisposed embryos. 
However, Eriksson's data in rats are inconsistent with human studies. In human 
studies, no significant differences were found in the incidence of congenital 
malformation in the offspring of diabetic and non-diabetic fathers (Comess et 
a/., 1969; Chung and Myrianthopoulos, 1975). The anomaly rates, however, 
were found to be significantly higher among infants whose mothers were 
diabetic compared with offspring of normal parents. These human data do not 
support, although do not entirely exclude, a genetic factor as a major 
determinant of diabetes-associated congenital malformations (Eriksson et a/., 
1986). 
1.4.6 Other Maternal Factors 
A variety of additional factors shown to be associated with diabetic 
malformation have also been investigated. Zinc deficiency has been reported in 
a few clinical studies as a cause of fetal malformation (Eriksson, 1984). A 
decrease in zinc content has been demonstrated in the rat offspring of diabetic 
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mother, however, the exact role of zinc deficiency in diabetes-related 
embryopathy remains to be elucidaied (Eriksson, 1984 ). 
Insulin, which is teratogenic in chickens. (Julian and Abbott, 1998), 
produces no abnormalities when added in very high concentrations (250 times 
physiologic) to mouse embryos (Sadler and Horton, 1983). Moreover, serum 
collected from diabetic rats receiving insulin therapy is less teratogenic than that 
collected from diabetic animals receiving no insulin supplements (Wentzel and 
Eriksson, 1996). 
1.5 FUEL-MEDIATED TERATOGENESIS 
Earlier concept in developmental biology implies that the damaged 
preimplantation embryos would either abort at the time of implantation or 
survive free of anomalies (Russell and Russell, 1950). This concept has been 
challenged by observations that alterations in the embryonic milieu or exposure 
to certain agents before implantation can contribute to the occurrence of fetal 
abnormalities long after the time of the primary insult (Freinkel and Metzger, 
1978, Iannaccone eta!., 1987, Kimmel eta/., 1993). 
The concept of "pregnancy as a tissue culture experience" is still 
accepted until today. It was first introduced by Freinkel and Metzger (1978). 
This concept proposed that the placenta and the fetus develop in an incubating 
medium that is totally derived from maternal metabolites. The latter cross the 
placenta in a concentration-dependent fashion, and this limits the incubation 
medium in the fetal circulation. Since all these constituents are mainly regulated 
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by maternal insulin, disturbances in its supply and action will influence the 
whole nutrient composition to which the fetus is exposed and may lead to fetal 
hyperinsulinemia. 
Based on this concept, the abnormal maternal mixture of metabolites 
gains access to the developing fetus in utero, modifying the phenotypic gene 
expression in newly formed cells, which in turn may lead to short- and long-term 
effects in the offspring. The fetal tissues most likely to be affected are neural 
cells, adipocytes, muscle cells and pancreatic ~-cells. Exposure during the early 
first trimester can lead to early intrauterine growth retardation and organ 
malformations, described by Freinkel as 'fuel-mediated teratogenesis'. During 
the second trimester, when the formation and development of the brain cells 
take place, altered behavioral, intellectual or psychological patterns may occur. 
During the third trimester, proliferation of fetal adipocytes, muscle cells, 
pancreatic ~-cells and neuroendocrine systems is the basis for development 
later in life of obesity or type 2 diabetes mellitus. 
1.6 INSULIN-LIKE GROWTH FACTORS (IGFs) 
The present understanding of IGFs results from a union of knowledg~ 
from three different areas of research (i) the mediators of the growth promoting 
actions of growth hormone (GH), namely sulfation factor activity, SFA (Salmon 
and Daughaday, 1957), (ii) the nature of the non-suppressible insulin-like 
activity in serum, NSILA (Froesch eta/., 1963), and (iii) the identity of serum 
factors that stimulate cellular multiplication in vitro, namely multiplication-
stimulating activity, MSA (Dulak and Temin 1973). 
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The term "somatomedin" was introduced to replace the terms SFA, 
NSILA and MSA (Daughaday et a/., 1972) This term was later replaced by 
IGFs (Daughaday and Rotwein 1989). 
The components of the IGFs system include (i) IGF-1, IGF-2 and insulin: 
(ii) their corresponding receptors, IGF-1 R, IGF-2R and insulin receptors (IR); (iii) 
six IGFs binding proteins (IGFBP 1-6); (iv) nine additional IGFBP-related 
proteins (IGFBP-rPs 1-9); (v) IGFBP cleaving proteases; (vi) and a glycoprotein 
known as acid-labile subunit (ALS) (Clemmons, 1993; Cohick and Clemmons, 
1993; LeRoith eta/., 1995; Collett-Solberg and Cohen, 2000). 
1.7 INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) 
IGF-1 is a 7649 Dalton (Da) single-chain polypeptide with three 
intrachain disulphide bridges consisting of 70 amino acids (Rinderknecht and 
Humbel, 1978a). Structurally IGF-1 is divided into domains A and B (similar to 
insulin), domain C (analogous to the connecting peptide (C-peptide) of 
proinsulin but no sequence homology to C-peptide of insulin) and domain D (not 
present in insulin). IGF-1 displays approximately 62 percent sequence 
homology with IGF-2 and 47 percent with insulin. 
The primary structure of IGF-1 has been characterized in five 
mammalian species. Bovine, porcine and human IGF-1 are identical, whereas 
rat and mouse IGF-1 differ from human by three and four amino acid residues, 
respectively. Only one amino acid residue difference is observed between rat 
and mouse IGF-1 (Rinderknecht and Humbel, 1978a; Bell et a/., 1986; 
23 
Honegger and Humbel, 1986: Murphy et a!., 1987a; Shimatsu and Rotwein, 
1987a & 1987b; Tavakkol eta!., 1988). 
In addition to the classical IGF-1 molecules, a truncated form of IGF-1 
known as DES (1-3) IGF-1 has been isolated from human fetal tissue (Sara et 
a!., 1986) and adult brain (Carlsson-Skwirut eta/., 1986) as well as from bovine 
colostrum (Francis et a/., 1986). DES (1-3) IGF-1 is the product of 
posttranslational modification of proiGF-1 lacking the first three residues at the 
amino terminus: Gly-Pro-Giu. The biologic potency of this truncated form is 10 
times higher than that of the full length form and is explained by reduced 
binding to IGFBP (Francis eta/., 1988; Carlsson-Skwirut eta/., 1989; Simes et 
a/., 1991; Becket a/., 1993; Ballard eta/., 1996). 
17.1 IGF-1 gene 
The IGF-1 gene consists of six exons, five introns and is transcribed from 
two promoters as shown in Figure 1.5 (Rotwein, 1991, Zarrilli eta/., 1994). It 
spans a large region of chromosomal DNA, ranging in size from 50 kilobase 
(kb) in the chicken to 80 kb in the rat; the human gene is localized on 
chromosome region 12q22-q24.1 (Brissenden eta/., 1984; Zar(illi eta/., 1994). 
Exons 1 and 2 are leader exons, and encode 5' untranslated regions and 
signal peptide sequences. From the two leader exons, two types of IGF-1 
transcripts are encoded (Hallet a/., 1992; Shemer eta/., 1992; Pellet a/., 1993; 
Yang eta/., 1995a). Exon 1 transcripts are found in all tissues and regulated by 
factors other than GH. It represents the "autocrine and/or paracrine 
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